申请人主要从事DNA损伤与癌症发生的研究。主要研究成果：1）首次在分子层面上建立PARP与BRCA1的联系，揭示PARP抑制剂杀伤BRCA1缺陷卵巢癌或乳腺癌的分子机制；2）发现并定义新一类PAR结合蛋白，拓展PARP抑制剂癌症化疗范围；3）揭示微管与纺锤体生物学特征，探讨微管结合剂类化疗药物在卵巢癌、卵巢功能维持的作用机制。共发表SCI论文28篇，包括Cancer Cell、Genes & Development、Oncogene等。论文总引用660次，他引504次。作为中组部“青年千人”、北京大学“百人计划”研究员引进回国一年来，组建“DNA损伤与妇科肿瘤”实验室。主持或承担科研基金2项，包括国自然“创新研究群体”。本项目拟探讨雌激素相关活性氧(ROS)对BRCA1缺陷卵巢的致癌效应，旨在揭示卵巢癌发生的分子机制，为卵巢癌的早期诊断提供特异标志物，以及临床抗氧化物治疗提供新方向。

The applicant is focusing on the field of DNA damage and tumorigenesis. The main academic achievements included: 1) the applicant found the molecular link between PARP and BRCA1, and uncovered the mechanism of PARP inhibitor against BRCA1-deficient ovarian or breast cancer. 2) the applicant identified the novel proteins for binding PAR, which extended the cancer categories killed by PARP inhibitor. 3) the applicant characterized the biological behavior of tubulin and spindle, providing insight into the tubulin-binding agents for chemotherapy. The applicant has published 28 SCI papers, including 11 first-author and corresponding author. The representative papers were published in Cancer Cell、Genes & Development、Oncogene, etc. The total citation number of these papers is 660, with 504 times by other SCI papers. As the “1000-Plan (youth) of China”, and “100-Talent Plan in Peking University”, the applicant has set up the “DNA damage and gynecological oncology” lab in Peking University Third Hospital. The applicant is now in charge of or involved in two grants in China, including “Innovative Research Group” of the National Natural Science Foundation. In this current proposal, the applicant will study the relationship between estrogen-related ROS and ovarian cancer. This work will decipher the molecular mechanism of ovarian tumorigenesis, to provide the specific biomarker for the early diagnosis of ovarian cancer, and insight into the clinical treatment with antioxidant.